<DOC>
	<DOCNO>NCT01647893</DOCNO>
	<brief_summary>A Phase 1 Clinical Study , Randomized , Double-blind , Placebo-controlled , Single-dose , Dose Escalation Study Safety Pharmacokinetic/Pharmacodynamic Profiles CTB-001 Intravenously Administered Healthy Male Subjects</brief_summary>
	<brief_title>Phase 1 Single Dose Escalation Study CTB-001</brief_title>
	<detailed_description />
	<mesh_term>Mannitol</mesh_term>
	<criteria>Adult male age 20 40 year screen . Be able understand objective , method study , characteristic investigational drug , comply requirement study . Subject must provide write informed consent prior study participation . History presence liver , kidney , nervous system disease , respiratory disorder , endocrinological disorder , hematooncologic , cardiovascular psychiatric cognitive disorder . History gastrointestinal disorder ( bleed , ulceration , hemorrhoid , pile ) disorder absorption , distribution , metabolism , excretion . History known hypersensitivity drug include CTB001</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>